Business Context and Reporting Period
Company: Innate Pharma SA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 1, 2024 to June 30, 2024 (H1 2024)
Filing Date: September 12, 2024
Signatory: Hervé Brailly, Interim Chief Executive Officer
This filing incorporates by reference the H1 2024 Half-Year Financial Report (Exhibit 99.2). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided text contains only the cover page and exhibit index of the Form 6-K. It does not include the detailed financial statements or the Half-Year Financial Report (Exhibit 99.2) where specific numbers reside.
- Revenue: Not provided in the source text.
- Profit/Loss: Not provided in the source text.
- Cash Flow: Not provided in the source text.
- Margins: Not provided in the source text.
- Debt and Liquidity: Not provided in the source text.
Material Changes
The filing text does not provide comparative financial data or narrative descriptions of material changes versus the prior comparable period. Such information is expected to be contained within the referenced Exhibit 99.2, which is not included in the input.
Guidance, Outlook, and Risks
The provided text does not contain management commentary, forward-looking guidance, risk factors, contingencies, or descriptions of unusual items. These disclosures are typically found in the body of the Half-Year Financial Report referenced as Exhibit 99.2.
Investor Verification Checklist
- Verify the full content of Exhibit 99.2 (H1 2024 Half-Year Financial Report) to obtain actual revenue, net loss, and cash position figures.
- Confirm the status of the company's lead clinical programs and any regulatory updates not detailed in this cover sheet.
- Review the "Statutory Auditors' Review Report" (noted as excluded from incorporation by reference on page 43 of Exhibit 99.2) for any qualifications or emphasis of matter.
- Assess the implications of the leadership transition, noting the signatory is the Interim Chief Executive Officer.